TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02511145

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: occlusive bandage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: occlusive bandage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: occlusive bandage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ablative fractional CO2 laser pretreatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ablative fractional CO2 laser pretreatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ablative fractional CO2 laser pretreatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedles pretreatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedles pretreatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedles pretreatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METVIXIA Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METVIXIA Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METVIXIA Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METVIXIA Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METVIXIA Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: METVIXIA Cream
Study: NCT00611572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iomazenil
Description: Given as IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: iomazenil
Description: saline IV infusion
Study: NCT01450215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .
Study: NCT01328080

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Targeted UV-B
Description: Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Targeted UV-B
Description: Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)
Study: NCT02097238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03425084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: The study was designed as an open, non-controlled drug trial, with scientists and participants blinded to the patients OCT1 status. Morphine will be given as a single dosis (0,15 mg/kg) at the end of the Surgery and later as boluses of 0,04mg/kg administrated by patient-controlled analgesia, (PCA). Blood samples with drug concentrations will be used to determine a difference in morphine AUC due to the patients OCT1 status. Questionnaire answers will be used to determine the effect of morphine due to the patients OCT1 status
Study: NCT00665262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramacet
Description: 2 tablets every 6 hours for 5 days
Study: NCT01704118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel
Description: Supraglottic airway device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProSeal Laryngeal mask
Description: Supraglottic airway device
Study: NCT03598270

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Intravenous. Day 1
Study: NCT02639650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: actinomycin D
Description: actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h\*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin
Study: NCT00485732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
Study: NCT02307422

Intervention type: GENETIC
Intervention: IL-1 Genotypes, other SNPs associated with CAD
Description: Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).

Intervention type: GENETIC
Intervention: IL-1 Genotypes, other SNPs associated with CAD
Description: Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
Study: NCT02801747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart2 (HTH2)
Description: The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart2 (HTH2)
Description: The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart2 (HTH2)
Description: The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart2 (HTH2)
Description: The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart2 (HTH2)
Description: The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
Study: NCT01191125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical food with AN777
Description: Two(220 mL)servings every day for six months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral nutritional formula
Description: Two (220 mL) servings daily for six months
Study: NCT02875132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: pembrolizumab at 200mg IV infusion every 3 weeks
Study: NCT02539433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: F-18-F-DOPA
Description: F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
Study: NCT03598270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous. Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m². Intravenous. Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m². Intravenous. Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niraparib
Description: 200 mg or 300 mg. Oral. From day 1 to 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200 mg or 300 mg. Oral. From day 1 to 21

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m². Intravenous. Day 1 and day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m². Intravenous. Day 1 and day 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: 30 mg/m². Intravenous. Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: 30 mg/m². Intravenous. Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg. Intravenous. Day 1
Study: NCT02938598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Depression Education and Care-Seeking Motivation
Description: Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
Study: NCT02938598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Depression Education and Care-Seeking Motivation
Description: Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Depression Education and Care-Seeking Motivation
Description: Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Depression Education and Care-Seeking Motivation
Description: Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Depression Education and Care-Seeking Motivation
Description: Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Depression Education and Care-Seeking Motivation
Description: Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Depression Education and Care-Seeking Motivation
Description: Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Depression Education and Care-Seeking Motivation
Description: Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
Study: NCT01041638

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given IV or SC
Study: NCT00349453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Description: 50-100 mg/kg body weight daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Description: 75 mg/kg body weight daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desferrioxamine
Description: 35-50 mg/kg body weight on 2 or more days per week
Study: NCT01417741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Needle
Description: A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
Study: NCT01037179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
Study: NCT02930733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml %0,25 bupivacaine bilaterally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 ml saline subcutaneously bilaterally
Study: NCT01513668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Extended release Gel tabs 650 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Extended release Gel tabs 650 mg
Study: NCT02631109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2000U/m2 day5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25mg/m2 day1
Study: NCT03250858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised advice
Description: Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-personalised advice
Description: Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalized dietary advice for improved food choice based on standard population health guidelines.
Study: NCT04563910

Intervention type: OTHER
Intervention: young mania rating scale
Description: questionnaires to the patients and their family after their written consent
Study: NCT01395381

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: single dose albendazole given at the time of enrollment
Study: NCT00694603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given intravenously once per week.
Study: NCT02631109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m2 was administered once on the first day of every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
Study: NCT03867383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Chloride
Description: All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline
Study: NCT02191267

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18]-T807
Description: \[F18\]-T807 PET Scan to measure tau deposition in the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18]-T807
Description: \[F18\]-T807 PET Scan to measure tau deposition in the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18]-T807
Description: \[F18\]-T807 PET Scan to measure tau deposition in the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18]-Florbetapir
Description: \[F18\]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18]-Florbetapir
Description: \[F18\]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18]-Florbetapir
Description: \[F18\]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/MRS
Description: Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/MRS
Description: Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/MRS
Description: Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Analysis for Genetic Risk Score for Tau.
Description: DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
Study: NCT00599612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW856553
Description: A dose of 10mg GW856553 containing 50µCi of \[14C\]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
Study: NCT00955669

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptoms and Objective Examination
Description: 5.0\*108\~5.0\*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
Study: NCT00765674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150 and 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150 and 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150 and 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 and 10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 and 10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 and 10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: 12.5 and 25 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: 12.5 and 25 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: 12.5 and 25 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet
Study: NCT00765674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules
Study: NCT00360438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: 0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
Study: NCT04606355

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: autostereoscopic, monocular dynamic force choice test

Intervention type: DIAGNOSTIC_TEST
Intervention: stereopsis
Description: autostereoscopic dynamic forced-choice depth perception test
Study: NCT04359940

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: For clinical surveillance
Study: NCT00606554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-assisted weaning program
Description: Closed-loop, knowledge-based, computer-assisted wean program initiated at the start of ventilator weaning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care weaning
Description: Evidence-based standard of care weaning process.
Study: NCT04406181

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HADS
Description: Hospital Anxiety and Depression Scale
Study: NCT04606355

Intervention type: DIAGNOSTIC_TEST
Intervention: Color vision
Description: autostereoscopic forced choice monocular or binocular color vision tests
Study: NCT02002169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shower Technique Protocol
Description: Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard CVC Care
Description: Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CVC Care
Description: Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.